Cyclophosphamide Plus Rituximab Prevents AAV Relapses: Study
Adding a low dose of cyclophosphamide to rituximab for remission induction was safe and more effective at preventing relapses in the first two years in people with severe ANCA-associated vasculitis (AAV) than rituximab alone, a new study shows. No significant benefit was observed in the combination treatment after five years.